National Cancer Center, Korea   Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Goyang Korea, Republic of (2000)

Organization Overview

First Clinical Trial
2001
NCT00506168
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Bo Hyun Kim | Byung-Kiu Park | Center for Colorectal Cancer, National Cancer Center Korea | Chief, Center for Breast Cancer, National Cancer Center, Korea | Clinical Research Center for Solid Tumor, Korea | Clinical Research Center for Solid Tumors, Korea | Department of Breast and Medical Oncology, National Cancer Center Hospital | Hark Kyun Kim | Ji-youn Han | Jungsil Ro | Kim, Seoung-Hoon | Liver Cancer Center, National Cancer Center, Republic of Korea | National Cancer Center, Gyeonggi, Korea | National Cancer Center, Korea | National Cancer Center of Korea | National Cancer Center, Rep. of Korea | National Cancer Center, Republic of Korea | National Cancer Center, Seoul, Korea | National Cancer Center, South Korea | National Cencer Center, Korea | Pediatric Oncology Branch, National Cancer Center, Korea | Research Institute and Hospital, National Cancer Center Korea | Seung Duk Lee | Sokbom Kang

Active Ingredients

Drugs in Phase 4 Trials (1)

tacrolimus (prograf) (2 trials)

Drugs in Phase 3 Trials (36)

123 iodine (1 trial)

125-iodine (1 trial)

acetylsalicylic acid (aspirin) (1 trial)

bismuth (3 trials)

capecitabine (xeloda) (13 trials)

chlorhexidine (hibitane) (1 trial)

cisplatin (platinol) (18 trials)

clarithromycin (biaxin) (3 trials)

cyclophosphamide (cytoxan) (3 trials)

docetaxel (taxotere) (9 trials)

doxorubicin (Doxil) (4 trials)

erlotinib (tarceva) (5 trials)

etoposide (vepesid) (1 trial)

ferric carboxymaltose (Injectafer) (2 trials)

folic acid (1 trial)

gefitinib (iressa) (4 trials)

gimeracil (12 trials)

goserelin (zoladex) (2 trials)

irinotecan (Camptosar) (17 trials)

lansoprazole (prevacid) (3 trials)

levobupivacaine (chirocaine) (1 trial)

metronidazole (flagyl) (3 trials)

omeprazole (prilosec) (3 trials)

oteracil (12 trials)

oxaliplatin (eloxatin) (11 trials)

palbociclib (ibrance) (1 trial)

polyethylene glycol (3 trials)

povidone-iodine (1 trial)

procaine benzylpenicillin (novocaine) (3 trials)

rabeprazole (pariet) (1 trial)

s-1 (11 trials)

sodium chloride (1 trial)

suclear (1 trial)

tamoxifen (nolvadex) (4 trials)

tegafur (12 trials)

tetracycline (tetrex) (2 trials)

Drugs in Phase 2 Trials (50)

afatinib (gilotrif) (1 trial)

atezolizumab (tecentriq) (2 trials)

autologous dendritic cells (1 trial)

bevacizumab (avastin) (2 trials)

brentuximab vedotin (adcetris) (2 trials)

brigatinib (alunbrig) (1 trial)

bvac-c (1 trial)

cefotetan (cefotan) (1 trial)

cetuximab (erbitux) (2 trials)

citric acid (1 trial)

ckd602 (1 trial)

durvalumab (imfinzi) (2 trials)

everolimus (zortress) (2 trials)

fluorouracil (efudex) (1 trial)

gc-1118 (1 trial)

gemcitabine (gemzar) (15 trials)

ifosfamide (ifex) (1 trial)

indocyanine green (ic-green) (3 trials)

lapatinib (tykerb) (2 trials)

lenvatinib (lenvima) (1 trial)

letrozole (femara) (2 trials)

leuprolide (lupron) (1 trial)

lomustine (1 trial)

lorlatinib (lorbrena) (1 trial)

magnesium oxide (1 trial)

metformin (glucophage) (1 trial)

methotrexate (1 trial)

methylprednisolone (medrol) (1 trial)

mitomycin (mutamycin) (1 trial)

nintedanib (ofev) (1 trial)

nivolumab (opdivo) (2 trials)

norzyme (1 trial)

paclitaxel (taxol) (9 trials)

pembrolizumab (keytruda) (1 trial)

pemetrexed (alimta) (2 trials)

procarbazine (matulane) (1 trial)

recombinant human choriogonadotropin alfa (Ovidrel) (1 trial)

rogaratinib (1 trial)

simvastatin (zocor) (4 trials)

sodium phosphate (1 trial)

sodium picosulfate (3 trials)

sorafenib (nexavar) (2 trials)

sunitinib (sutent) (2 trials)

temozolomide (temodar) (1 trial)

titanium silicide (3 trials)

trastuzumab (herceptin) (3 trials)

trimagnesium dicitrate (1 trial)

vactosertib (1 trial)

vinorelbine (navelbine) (2 trials)

vitamin c (2 trials)

Drugs in Other Trials (4)

ethambutol (myambutol) (1 trial)

isoniazid (nydrazid) (1 trial)

pyrazinamide (Aldinamide) (1 trial)

rifampin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Adenocarcinoma (Phase 3)

Adenocarcinoma of Lung (Phase 2)

Anemia (Phase 3)

Astrocytoma (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cholangiocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 3)

Esophageal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hodgkin Disease (Phase 2)

Immunoblastic Lymphadenopathy (Phase 2)

Infections (Phase 2)

Lung Injury (Phase 2)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Meningeal Carcinomatosis (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Osteosarcoma (Phase 2)

Pancreatic Neoplasms (Phase 2)

Postoperative Complications (Phase 2)

Prostatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Recurrence (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Sarcoma (Phase 2)

Small Cell Lung Carcinoma (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 3)

Surgical Wound Infection (Phase 3)

Syndrome (Phase 2)

Thyroid Diseases (Phase 3)

Thyroid Neoplasms (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 115
  • # of Trial APIs: 91